APA (7th ed.) Citation

S, N., E, I., Y, M., A, N., K, F., H, U., . . . M, I. (2018). Novel increasing dose regimen of tolvaptan for autosomal dominant polycystic kidney disease in patient with low tolerability. Nephrology (Carlton, Vic.), 23(8), 798. https://doi.org/10.1111/nep.13196

Chicago Style (17th ed.) Citation

S, Nakatani, et al. "Novel Increasing Dose Regimen of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Patient with Low Tolerability." Nephrology (Carlton, Vic.) 23, no. 8 (2018): 798. https://doi.org/10.1111/nep.13196.

MLA (9th ed.) Citation

S, Nakatani, et al. "Novel Increasing Dose Regimen of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in Patient with Low Tolerability." Nephrology (Carlton, Vic.), vol. 23, no. 8, 2018, p. 798, https://doi.org/10.1111/nep.13196.